Migräneprophylaxe – alles nur noch Antikörper?

Hamann, Till; Kamm, Katharina; Kropp, Peter; Rimmele, Florian; Jürgens, Tim P.

doi:10.1007/s00482-020-00500-x

Cited by 2 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 It is currently the first and only 5-HT1F receptor agonist approved by the Food and Drug Administration. 45 In addition, analysis of the drug's efficacy found that a dose of 200 mg is more effective than a dose of 100 mg. 46 The prevention of migraine should be combined with non-drug measures, 47 such as avoiding triggers, 17 controlling weight, 48 and maintaining a good lifestyle; cognitive behavioral therapy 49 can also reduce the frequency of migraine attacks. The pharmacological treatments for migraine prevention include β-receptor antagonists, 2 calcium channel blockers, 8,13,15,37,38 anti-epileptics, 37,39 and tricyclic antidepressants.…”

Section: Treatment and Outlookmentioning

confidence: 99%

Migraine with Brainstem Aura Accompanied by Disorders of Consciousness

Xu¹,

Li²,

Huang³

et al. 2021

JPR

View full text Add to dashboard Cite

Migraine with brainstem aura (MBA) accompanied by disorders of consciousness (DOC) is a rare subtype of migraine. The pathophysiology of MBA with DOC has not been elucidated yet. Some patients have a family history of migraine, and women are more affected than men. The aura symptoms are diverse; however, when MBA is combined with DOC, the clinical manifestations are more complicated. Coma is the most common clinical manifestation. The overall duration of the patient’s DOC is short and can often return to normal within half an hour. Headache often occurs after regaining consciousness and can also occur at the same time as DOC. The most common headache is located at the occipital region. Although DOC is reversible, considering the current small number of cases, we still need to improve our understanding of the disease to avoid misdiagnosis. The MBA patient’s electroencephalogram and cerebral blood flow perfusion may have transient changes and may return to normal in the interictal period or after the DOC. Although triptans have traditionally been contraindicated in MBA under drug instructions, the evidence of basilar artery constriction, as postulated in MBA, is lacking. Lasmiditan is currently the first and only 5-HT 1F receptor agonist approved by the Food and Drug Administration. The calcitonin gene-related peptide receptor antagonists and monoclonal antibody therapies may be the most promising for future consideration. Here, the pathophysiology, clinical manifestations, diagnostic tools, and treatment progress for MBA with DOC are reviewed.

show abstract